Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ZyVersa Therapeutics, Inc. - Common Stock (NQ:ZVSA)

0.6090 +0.0217 (+3.69%)
Streaming Delayed Price Updated: 3:55 PM EDT, Apr 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ZyVersa Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
ZyVersa Therapeutics Announces Publication of an Article in the Journal of Neuroinflammation Addressing the Role of ASC Specks in Propagation of Alpha-Synuclein Pathology in Parkinson’s Disease
From ZyVersa Therapeutics
Via GlobeNewswire
Why IDEAYA Biosciences Shares Are Trading Higher By Around 27%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Aclarion, Inc. (NASDAQ: ACON) shares surged 152% to $1.85 amid the publication of durability data for the company's back pain treatment. 
Via Benzinga
Why Is ZyVersa Therapeutics (ZVSA) Stock Up 35% Today?
ZyVersa Therapeutics (ZVSA) stock is taking off on Thursday morning without any recent news from the biopharmaceutical company. 
Via InvestorPlace
ZyVersa Therapeutics Adds Dr. Douglas Golenbock to Its Inflammatory Disease Scientific Advisory Board to Support Advancement of Inflammasome ASC Inhibitor IC 100
From ZyVersa Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Keynotes, Educational Panels and 77 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 25-27, 2023 at the Horseshoe Hotel & Casino in Las Vegas, NV
Via ACCESSWIRE
Why Bed Bath & Beyond Shares Are Trading Lower By Around 38%; Here Are 20 Stocks Moving Premarket
Gainers ZyVersa Therapeutics, Inc. (NASDAQ: ZVSA) gained 118% to $3.64 in pre-market trading after declining around 5% on Friday. ZyVersa Therapeutics recently posted a wider FY loss. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
We're starting off the week with the biggest pre-market stock movers that traders will want to keep an eye on for Monday morning! 
Via InvestorPlace
ZyVersa: This Drug Maker Is Targeting Critical Diseases With Novel Approaches
Steve Glover, Co-Founder, Chairman, CEO, & President of ZyVersa Therapeutics, Inc. (NASDAQ: ZVSA), was recently a guest on Benzinga’s All-Access. 
Via Benzinga
ZyVersa Therapeutics Announces Article Published in Biomaterials Addressing the Critical Role of Inflammasome Activation in Neuroinflammation Resulting from Intracortical Implants
From ZyVersa Therapeutics
Via GlobeNewswire
ZyVersa Therapeutics Announces Review Article Published in Frontiers in Pharmacology Addressing Microglial Inflammatory Activity as a Pharmacological Target in Mild Cognitive Impairment and Alzheimer’s Disease
From ZyVersa Therapeutics
Via GlobeNewswire
ZyVersa Therapeutics’ CEO, Stephen C. Glover to Appear on Benzinga 'All Access'
From ZyVersa Therapeutics
Via GlobeNewswire
Why iMedia Brands Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket
Gainers HeartCore Enterprises, Inc. (NASDAQ: HTCR) jumped 119.6% to $1.96 in pre-market trading. HeartCore forged an agreement with rYojbaba Inc for its tenth Go IPO consulting service win. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Pre-market stock movers are a hot topic on Wednesday as we dive into all of the latest news affecting markets this morning. 
Via InvestorPlace
ZyVersa Therapeutics' CEO, Stephen C. Glover, to Present at Planet MicroCap Showcase
From ZyVersa Therapeutics
Via GlobeNewswire
ZyVersa Therapeutics Announces Article Published in Brain Pathology Addressing Inflammasome Signaling Proteins in Alzheimer’s Disease
From ZyVersa Therapeutics
Via GlobeNewswire
ZyVersa Therapeutics Reports Fourth Quarter and Year-End 2022 Corporate and Financial Results
From ZyVersa Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Why Is Cidara Therapeutics (CDTX) Stock Down 12% Today?
Cidara Therapeutics (CDTX) stock is falling on Thursday despite the immunotherapy company getting positive news from the FDA. 
Via InvestorPlace
Why Block Shares Are Trading Lower By Over 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers DiamondHead Holdings Corp. (NASDAQ: DHHC) shares jumped 104.2% to $21.15. DiamondHead entered into convertible note purchase agreement dated March 21, 2023. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Why Is Coinbase (COIN) Stock Down 15% Today?
Coinbase Global (COIN) stock is falling on Thursday after the SEC threatened to investigate the crypto exchange's business. 
Via InvestorPlace
Why Is Advent Technologies (ADN) Stock Up 32% Today?
Advent Technologies (ADN) stock is climbing higher on Thursday following news of a fuel cell agreement with Hyundai (HYMTF). 
Via InvestorPlace
Why Agile Therapeutics Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket
Gainers ZyVersa Therapeutics, Inc. (NASDAQ: ZVSA) shares rose 82.8% to $2.98 in pre-market trading. ZyVersa Therapeutics recently reported new employment inducement grants under Nasdaq Listing Rule... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
We're starting off the day with a look at the biggest pre-market stock movers traders need to know about on Thursday morning! 
Via InvestorPlace
ZyVersa Therapeutics Reports New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From ZyVersa Therapeutics
Via GlobeNewswire
ZyVersa Therapeutics Adds Dr. Richard J. Glassock to Its Renal Scientific Advisory Board to Support Clinical Advancement of Renal Cholesterol Efflux Mediator™ VAR 200
From ZyVersa Therapeutics
Via GlobeNewswire
ZyVersa Therapeutics to Participate in a Fireside Chat at Oppenheimer Healthcare Conference
From ZyVersa Therapeutics
Via GlobeNewswire
ZyVersa Therapeutics to Participate in a Fireside Chat at Roth Annual Conference
From ZyVersa Therapeutics
Via GlobeNewswire
ZyVersa Therapeutics Announces New Publication in Translational Research Showing IC 100 Reduces Inflammasome Activation in Mouse Model for Alzheimer’s Disease Following Traumatic Brain Injury
From ZyVersa Therapeutics
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.